Complicated Pleural Infection is Associated With Prolonged Recovery and Reduced Functional Ability.
Humans
Male
Female
Quality of Life
Middle Aged
Aged
Recovery of Function
Surveys and Questionnaires
Tissue Plasminogen Activator
/ therapeutic use
Thrombolytic Therapy
/ methods
Treatment Outcome
Return to Work
/ statistics & numerical data
Fibrinolytic Agents
/ therapeutic use
Adult
Pleural Diseases
/ therapy
Journal
Journal of bronchology & interventional pulmonology
ISSN: 1948-8270
Titre abrégé: J Bronchology Interv Pulmonol
Pays: United States
ID NLM: 101496866
Informations de publication
Date de publication:
01 Oct 2024
01 Oct 2024
Historique:
received:
17
01
2024
accepted:
24
05
2024
medline:
22
7
2024
pubmed:
22
7
2024
entrez:
22
7
2024
Statut:
epublish
Résumé
Management of complicated pleural infections (CPIs) had historically been surgical; however, following the publication of the second multicenter intrapleural sepsis trial (MIST-2), combination tissue plasminogen (tPA) and dornase (DNase) offers a less invasive and effective treatment. Our aim was to assess the quality of life (QOL) and functional ability of patients' recovery from a CPI managed with either intrapleural fibrinolytic therapy (IPFT) or surgery. We identified 565 patients managed for a CPI between January 1, 2013 and March 31, 2018. There were 460 patients eligible for contact, attempted through 2 phone calls and one mailer. Two questionnaires were administered: the Short Form 36-Item Health Survey (SF-36) and a functional ability questionnaire. Contact was made in 35% (159/460) of patients, and 57% (90/159) completed the survey. Patients had lower QOL scores compared to average US citizens; those managed with surgery had higher scores in physical functioning (surgery: 80, IPFT: 70, P=0.040) but lower pain scores (surgery: 58, IPFT: 68, P=0.045). Of 52 patients who returned to work, 48% (25) reported an impact on their work effectiveness during recovery, similarly between management strategies (IPFT: 50%, 13/26 vs. surgery: 46%, 12/26; P=0.781). Patients with a CPI had a lower QOL compared with average US citizens. Surgically managed patients reported improved physical functioning but worse pain compared with patients managed with IPFT. Patients returned to work within 4 weeks of discharge, and nearly half reported their ability to work effectively was impacted by their recovery. With further research into recovery timelines, patients may be appropriately counselled for expectations.
Sections du résumé
BACKGROUND
BACKGROUND
Management of complicated pleural infections (CPIs) had historically been surgical; however, following the publication of the second multicenter intrapleural sepsis trial (MIST-2), combination tissue plasminogen (tPA) and dornase (DNase) offers a less invasive and effective treatment. Our aim was to assess the quality of life (QOL) and functional ability of patients' recovery from a CPI managed with either intrapleural fibrinolytic therapy (IPFT) or surgery.
METHODS
METHODS
We identified 565 patients managed for a CPI between January 1, 2013 and March 31, 2018. There were 460 patients eligible for contact, attempted through 2 phone calls and one mailer. Two questionnaires were administered: the Short Form 36-Item Health Survey (SF-36) and a functional ability questionnaire.
RESULTS
RESULTS
Contact was made in 35% (159/460) of patients, and 57% (90/159) completed the survey. Patients had lower QOL scores compared to average US citizens; those managed with surgery had higher scores in physical functioning (surgery: 80, IPFT: 70, P=0.040) but lower pain scores (surgery: 58, IPFT: 68, P=0.045). Of 52 patients who returned to work, 48% (25) reported an impact on their work effectiveness during recovery, similarly between management strategies (IPFT: 50%, 13/26 vs. surgery: 46%, 12/26; P=0.781).
CONCLUSION
CONCLUSIONS
Patients with a CPI had a lower QOL compared with average US citizens. Surgically managed patients reported improved physical functioning but worse pain compared with patients managed with IPFT. Patients returned to work within 4 weeks of discharge, and nearly half reported their ability to work effectively was impacted by their recovery. With further research into recovery timelines, patients may be appropriately counselled for expectations.
Identifiants
pubmed: 39037060
doi: 10.1097/LBR.0000000000000974
pii: 01436970-202410010-00001
pii:
doi:
Substances chimiques
Tissue Plasminogen Activator
EC 3.4.21.68
Fibrinolytic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure: There is no conflict of interest or other disclosures.
Références
Colice GL, Curtis A, Deslauriers J, et al. Medical and surgical treatment of parapneumonic effusions: An evidence-based guideline. Chest. 2000;118:1158–1171.
Rahman NM, Maskell NA, West A, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med. 2011;365:518–526.
Kheir F, Thakore S, Mehta H, et al. Intrapleural fibrinolytic therapy versus early medical thoracoscopy for treatment of pleural infection randomized controlled clinical trial. Ann Am Thorac Soc. 2020;17:958–964.
Shin JA, Chang YS, Kim TH, et al. Surgical decortication as the first-line treatment for pleural empyema. J Thorac Cardiovasc Surg. 2013;145:933–939.e1.
Farjah F, Symons RG, Krishnadasan B, et al. Management of pleural space infections: a population-based analysis. J Thorac Cardiovasc Surg. 2007;133:346–351.e1.
Moores DWO. Management of acute empyema. Chest. 1992;102:1316–1317.
Shen KR, Bribriesco A, Crabtree T, et al. AATS consensus guidelines for the management of empyema. J Thorac Cardiovasc Surg. 2017;153:e129–e146.
Casali C, Storelli ES, Di Prima E, et al. Long-term functional results after surgical treatment of parapneumonic thoracic empyema. Interact Cardiovasc Thorac Surg. 2009;9:74–78.
Cardillo G, Carleo F, Carbone L, et al. Chronic postpneumonic pleural empyema: Comparative merits of thoracoscopic versus open decortication. Eur J Cardiothorac Surg. 2009;36:914–918.
Metlay JP, Atlas SJ, Borowsky LH, et al. Time course of symptom resolution in patients with community-acquired pneumonia. Respir Med. 1998;92:1137–1142.
American Lung Association Scientific and Medical Editorial Review Panel. What causes pneumonia? American Lung Association. 2021. https://www.lung.org/lung-health-diseases/lung-disease-lookup/pneumonia/what-causes-pneumonia
Mangen MJJ, Huijts SM, Bonten MJM, et al. The impact of community-acquired pneumonia on the health-related quality-of-life in elderly. BMC Infect Dis. 2017;17:208.
Wilshire CL, Jackson AS, Meggyesy AM, et al. Comparing initial surgery versus fibrinolytics for pleural space infections: a retrospective multicenter cohort study. Ann Am Thorac Soc. 2022;19:1827–1833.
36-Item short form survey (SF-36) scoring instructions. RAND Corporation. 2022. https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form/scoring.html
Ware JE Jr, Kosinski M, Gandek B. The SF-36 health survey: manual and interpretation guide. Boston, Massachusetts: The Health Institute, New England Medical Center; 1993.
Wyrwich KW, Yu H, Sato R, et al. Observational longitudinal study of symptom burden and time for recovery from community-acquired pneumonia reported by older adults surveyed nationwide using the CAP Burden of Illness Questionnaire. Patient Relat Outcome Meas. 2015;6:215.
Daniel P, Bewick T, McKeever TM, et al. Healthcare reconsultation in working-age adults following hospitalisation for community-acquired pneumonia. Clinical Medicine. 2018;18:41–46.
Labarere J, Stone RA, Obrosky DS, et al. Comparison of outcomes for low-risk outpatients and inpatients with pneumonia: a propensity-adjusted analysis. Chest. 2007;131:480–488.
Pick HJ, Bolton CE, Lim WS, et al. Patient-reported outcome measures in the recovery of adults hospitalised with community-acquired pneumonia: a systematic review. Eur Respir J. 2019;53:1802165.
Davydow DS, Hough CL, Levine DA, et al. Functional disability, cognitive impairment, and depression following hospitalization for pneumonia. Am J Med. 2013;126:615–624.
Council NR. Nonresponse in social science surveys: a research agenda. Washington D.C.: The National Academies Press; 2013. Epub ahead of print. doi:10.17226/18293
Edelman LS, Yang R, Guymon M, et al. Survey methods and response rates among rural community dwelling older adults. Nurs Res. 2013;62:286–291.
Hayes V, Morris J, Wolfe C, et al. The SF-36 health survey questionnaire: Is it suitable for use with older adults? Age Ageing. 1995;24:120–125.
Kujawa A, Green H, Compas BE, et al. Exposure to COVID-19 pandemic stress: Associations with depression and anxiety in emerging adults in the United States. Depress Anxiety. 2020;37:1280–1288.
Liu CH, Stevens C, Conrad RC, et al. Evidence for elevated psychiatric distress, poor sleep, and quality of life concerns during the COVID-19 pandemic among US young adults with suspected and reported psychiatric diagnoses. Psychiatry Res. 2020;292:113345.